WO2016201434A3 - Stable formulations of humanized anti-tau antibody - Google Patents

Stable formulations of humanized anti-tau antibody Download PDF

Info

Publication number
WO2016201434A3
WO2016201434A3 PCT/US2016/037236 US2016037236W WO2016201434A3 WO 2016201434 A3 WO2016201434 A3 WO 2016201434A3 US 2016037236 W US2016037236 W US 2016037236W WO 2016201434 A3 WO2016201434 A3 WO 2016201434A3
Authority
WO
WIPO (PCT)
Prior art keywords
humanized anti
tau antibody
stable formulations
tau
stable
Prior art date
Application number
PCT/US2016/037236
Other languages
French (fr)
Other versions
WO2016201434A2 (en
Inventor
Elizabeth JOHN
Philip VERGHESE
Helen HU
Matthias KRON
Katja Zipfel
Alexander FAUDE
Original Assignee
C2N Diagnostics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C2N Diagnostics, Llc filed Critical C2N Diagnostics, Llc
Priority to US15/735,728 priority Critical patent/US20200030445A1/en
Priority to EP16808523.1A priority patent/EP3307320A4/en
Publication of WO2016201434A2 publication Critical patent/WO2016201434A2/en
Publication of WO2016201434A3 publication Critical patent/WO2016201434A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

Provided herein are stable compositions containing anti-tau antibodies. In particular, compositions containing C2N-8E12 anti-tau antibody and a buffering system are provided herein.
PCT/US2016/037236 2015-06-12 2016-06-13 Stable formulations of humanized anti-tau antibody WO2016201434A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/735,728 US20200030445A1 (en) 2015-06-12 2016-06-13 Stable formulations of humanized anti-tau antibody
EP16808523.1A EP3307320A4 (en) 2015-06-12 2016-06-13 Stable formulations of humanized anti-tau antibody

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562175154P 2015-06-12 2015-06-12
US62/175,154 2015-06-12

Publications (2)

Publication Number Publication Date
WO2016201434A2 WO2016201434A2 (en) 2016-12-15
WO2016201434A3 true WO2016201434A3 (en) 2017-02-09

Family

ID=57504396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/037236 WO2016201434A2 (en) 2015-06-12 2016-06-13 Stable formulations of humanized anti-tau antibody

Country Status (3)

Country Link
US (1) US20200030445A1 (en)
EP (1) EP3307320A4 (en)
WO (1) WO2016201434A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20152004A1 (en) 2013-03-13 2016-02-07 Prothena Biosciences Ltd IMMUNOTHERAPY TAU
TWI790642B (en) 2015-06-05 2023-01-21 美商建南德克公司 Anti-tau antibodies and methods of use
KR102506091B1 (en) 2016-05-02 2023-03-07 프로테나 바이오사이언시즈 리미티드 Tau Immunotherapy
CU24537B1 (en) 2016-05-02 2021-07-02 Prothena Biosciences Ltd MONOCLONAL ANTIBODIES COMPETING TO JOIN HUMAN TAU WITH THE 3D6 ANTIBODY
KR20230146126A (en) 2016-12-07 2023-10-18 제넨테크, 인크. Anti-tau antibodies and methods of use
CN110248959B (en) 2016-12-07 2023-06-30 基因泰克公司 anti-TAU antibodies and methods of use
AU2018263935A1 (en) 2017-05-02 2019-12-19 Prothena Biosciences Limited Antibodies recognizing tau
JP2021519268A (en) * 2018-03-23 2021-08-10 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Stable aqueous anti-tau antibody preparation
JP2022524588A (en) 2019-03-03 2022-05-09 プロセナ バイオサイエンシーズ リミテッド Tau recognition antibody

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120230982A1 (en) * 2002-09-06 2012-09-13 Alexion Pharmaceuticals, Inc. High concentration antibody formulations
WO2014020171A1 (en) * 2012-08-03 2014-02-06 Boehringer Ingelheim International Gmbh Buffer capacity of antibodies
US20140086921A1 (en) * 2012-08-16 2014-03-27 Ipierian, Inc. Methods of Treating a Tauopathy
WO2015200806A2 (en) * 2014-06-27 2015-12-30 C2N Diagnostics Llc Humanized anti-tau antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120230982A1 (en) * 2002-09-06 2012-09-13 Alexion Pharmaceuticals, Inc. High concentration antibody formulations
WO2014020171A1 (en) * 2012-08-03 2014-02-06 Boehringer Ingelheim International Gmbh Buffer capacity of antibodies
US20140086921A1 (en) * 2012-08-16 2014-03-27 Ipierian, Inc. Methods of Treating a Tauopathy
WO2015200806A2 (en) * 2014-06-27 2015-12-30 C2N Diagnostics Llc Humanized anti-tau antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATYK ET AL.: "Hiyh-Pressure (+)-Sucrose Polymorph", ANGEW. CHEM. INT. ED., vol. 51, 2012, pages 2146 - 2150, XP055362004 *
See also references of EP3307320A4 *

Also Published As

Publication number Publication date
EP3307320A2 (en) 2018-04-18
WO2016201434A2 (en) 2016-12-15
US20200030445A1 (en) 2020-01-30
EP3307320A4 (en) 2019-03-06

Similar Documents

Publication Publication Date Title
WO2016201434A3 (en) Stable formulations of humanized anti-tau antibody
EP3436482A4 (en) Antibodies, pharmaceutical compositions and methods
EP3505535A4 (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
IL268588A (en) Anti-gprc5d antibodies, compositions comprising same and uses thereof
EP3309177A4 (en) Pdl-1 antibody, pharmaceutical composition thereof, and uses thereof
IL262497A (en) Anti-il-33 antibodies, compositions, methods and uses thereof
WO2018109170A3 (en) Il-11ra antibodies
EP3778648A4 (en) Novel antibody molecule, and preparation method and use thereof
EP3597735A4 (en) Ctla4 antibody, pharmaceutical composition and use thereof
SG10201803042PA (en) Anti-tim-3 antibodies
EP3359193A4 (en) Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
WO2017214458A3 (en) Anti-cd98 antibodies and antibody drug conjugates
WO2015127136A3 (en) Ebola monoclonal antibodies
EP3491026A4 (en) Human antibodies, pharmaceutical compositions and methods
EP3589648A4 (en) Anti-rsv monoclonal antibody formulation
EP3411069A4 (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
WO2017214462A3 (en) Anti-cd98 antibodies and antibody drug conjugates
IL283754A (en) Anti-claudin antibodies, compositions comprising same and uses thereof
EP3129048A4 (en) Antibodies, pharmaceutical compositions and uses thereof
EP3561057A4 (en) Anti-cd3 antibody, and molecule containing said antibody
MY185802A (en) Antibody formulation
EP3563868A4 (en) Pharmaceutical preparation stably comprising cd147 monoclonal antibody
EP4067387A4 (en) Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof
IL286100A (en) Anti-il-36r antibody formulations
IL285651A (en) Anti-trem2 antibodies, compositions comprising same and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16808523

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016808523

Country of ref document: EP